159 related articles for article (PubMed ID: 14992588)
1. G-rich oligonucleotide inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly reduces cell growth in human carcinoma pancreatic cells.
Cogoi S; Quadrifoglio F; Xodo LE
Biochemistry; 2004 Mar; 43(9):2512-23. PubMed ID: 14992588
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein binding.
Cogoi S; Ballico M; Bonora GM; Xodo LE
Cancer Gene Ther; 2004 Jul; 11(7):465-76. PubMed ID: 15118760
[TBL] [Abstract][Full Text] [Related]
3. Influence of GC and AT specific DNA minor groove binding drugs on intermolecular triplex formation in the human c-Ki-ras promoter.
Vigneswaran N; Mayfield CA; Rodu B; James R; Kim HG; Miller DM
Biochemistry; 1996 Jan; 35(4):1106-14. PubMed ID: 8573565
[TBL] [Abstract][Full Text] [Related]
4. (A,G)-oligonucleotides form extraordinary stable triple helices with a critical R.Y sequence of the murine c-Ki-ras promoter and inhibit transcription in transfected NIH 3T3 cells.
Alunni-Fabbroni M; Pirulli D; Manzini G; Xodo LE
Biochemistry; 1996 Dec; 35(50):16361-9. PubMed ID: 8973212
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1.
Fensterer H; Giehl K; Buchholz M; Ellenrieder V; Buck A; Kestler HA; Adler G; Gierschik P; Gress TM
Genes Chromosomes Cancer; 2004 Mar; 39(3):224-35. PubMed ID: 14732924
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of nuclear protein binding to the human Ki-ras promoter by triplex-forming oligonucleotides.
Mayfield C; Squibb M; Miller D
Biochemistry; 1994 Mar; 33(11):3358-63. PubMed ID: 8136373
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
9. A novel triplex-forming oligonucleotide targeted to human cyclin D1 (bcl-1, proto-oncogene) promoter inhibits transcription in HeLa cells.
Kim HG; Miller DM
Biochemistry; 1998 Feb; 37(8):2666-72. PubMed ID: 9485417
[TBL] [Abstract][Full Text] [Related]
10. Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide.
Cogoi S; Codognotto A; Rapozzi V; Meeuwenoord N; van der Marel G; Xodo LE
Biochemistry; 2005 Aug; 44(31):10510-9. PubMed ID: 16060660
[TBL] [Abstract][Full Text] [Related]
11. Ki-ras activation in vitro affects G1 and G2M cell-cycle transit times and apoptosis.
Orecchia R; Infusini E; Sciutto A; Rapallo A; Di Vinci A; Nigro S; Geido E; Giaretti W
J Pathol; 2000 Mar; 190(4):423-9. PubMed ID: 10699990
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38.
Dreissigacker U; Mueller MS; Unger M; Siegert P; Genze F; Gierschik P; Giehl K
Cell Signal; 2006 Aug; 18(8):1156-68. PubMed ID: 16257181
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of c-Ki-ras promoter activity by triplex-forming oligonucleotides endogenously generated in human 293 cells.
Cogoi S; Suraci C; Del Terra E; Diviacco S; van der Marel G; van Boom J; Quadrifoglio F; Xodo L
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):283-95. PubMed ID: 10984122
[TBL] [Abstract][Full Text] [Related]
14. Ras-dependent recruitment of c-Myc for transcriptional activation of nucleophosmin/B23 in highly malignant U1 bladder cancer cells.
Yeh CW; Huang SS; Lee RP; Yung BY
Mol Pharmacol; 2006 Oct; 70(4):1443-53. PubMed ID: 16857742
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new G-quadruplex motif in the KRAS promoter and design of pyrene-modified G4-decoys with antiproliferative activity in pancreatic cancer cells.
Cogoi S; Paramasivam M; Filichev V; Géci I; Pedersen EB; Xodo LE
J Med Chem; 2009 Jan; 52(2):564-8. PubMed ID: 19099510
[TBL] [Abstract][Full Text] [Related]
16. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
[TBL] [Abstract][Full Text] [Related]
17. Intra- and intermolecular triplex DNA formation in the murine c-myb proto-oncogene promoter are inhibited by mithramycin.
Vigneswaran N; Thayaparan J; Knops J; Trent J; Potaman V; Miller DM; Zacharias W
Biol Chem; 2001 Feb; 382(2):329-42. PubMed ID: 11308031
[TBL] [Abstract][Full Text] [Related]
18. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
[TBL] [Abstract][Full Text] [Related]
19. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells.
Ignatenko NA; Babbar N; Mehta D; Casero RA; Gerner EW
Mol Carcinog; 2004 Feb; 39(2):91-102. PubMed ID: 14750214
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
Dong K; Wang R; Wang X; Lin F; Shen JJ; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Feb; 113(3):443-56. PubMed ID: 18327707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
